Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 12/20 | 0.51 |
| ▸ | MMP2 | P08253 | 12/20 | 0.51 |
| ▸ | MMP3 | P08254 | 5/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 7/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | ADAM8 | P78325 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172899 | 0.91 | ADAM10 (0.62) | ADAM10MMP2MMP3ERBB2MMP9 | |
| SCHEMBL2173377 | 0.89 | ADAM10 (0.48) | ADAM10MMP2MMP3ERBB2MMP9 | |
| SCHEMBL2176677 | 0.89 | ADAM10 (0.49) | ADAM10MMP2MMP3ERBB2ALDH1A1 | |
| SCHEMBL2176679 | 0.88 | ADAM10 (0.49) | ADAM10MMP2MMP3ERBB2ALDH1A1 | |
| SCHEMBL3458715 | 0.82 | ADAM10 (0.67) | ADAM10MMP2MMP3ERBB2ALDH1A1 | |
| SCHEMBL1365139 | 0.81 | ADAM10 (0.72) | ADAM10MMP2MMP3ERBB2MMP9 | |
| SCHEMBL1367674 | 0.81 | ADAM10 (0.72) | ADAM10MMP2MMP3ERBB2MMP9 | |
| SCHEMBL6024689 | 0.76 | ADAM10 (0.36) | ADAM10MMP2MMP3 | |
| SCHEMBL2173383 | 0.76 | ADAM10 (0.43) | ADAM10MMP2MMP3ERBB2NAMPT | |
| SCHEMBL3456865 | 0.76 | ADAM10 (0.48) | ADAM10MMP2MMP3ERBB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | ADAM10 26/4885MMP2 2/4885MMP3 7/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | ADAM10 25/4885MMP2 5/4885MMP3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.